Protagonist Therapeutics (PTGX) Insider Trading & Ownership → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free PTGX Stock Alerts $25.15 +0.49 (+1.99%) (As of 04/26/2024 ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Protagonist Therapeutics (NASDAQ:PTGX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.00%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$2.68 M Get PTGX Insider Trade Alerts Want to know when executives and insiders are buying or selling Protagonist Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PTGX Insider Buying and Selling by Quarter Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. Protagonist Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/18/2024Asif AliCFOSell1,234$25.11$30,985.74 4/1/2024Dinesh V Ph D PatelCEOSell25,000$28.31$707,750.00 3/1/2024Asif AliCFOSell14,248$32.24$459,355.52 3/1/2024Dinesh V Ph D PatelCEOSell30,000$31.62$948,600.00 3/1/2024William D WaddillDirectorSell12,975$31.34$406,636.50 1/9/2024Suneel GuptaInsiderSell5,000$25.00$125,000.00 (Data available from 1/1/2013 forward) PTGX Insider Trading Activity - Frequently Asked Questions Who is on Protagonist Therapeutics's Insider Roster? The list of insiders at Protagonist Therapeutics includes Asif Ali, David Y. Liu, Dinesh V Ph D Patel, Suneel Gupta, and William D Waddill. Learn more on insiders at PTGX. What percentage of Protagonist Therapeutics stock is owned by insiders? 5.00% of Protagonist Therapeutics stock is owned by insiders. Learn more on PTGX's insider holdings. Which Protagonist Therapeutics insiders have been selling company stock? The following insiders have sold PTGX shares in the last 24 months: Asif Ali ($490,341.26), Dinesh V Ph D Patel ($1,656,350.00), Suneel Gupta ($125,000.00), and William D Waddill ($406,636.50). How much insider selling is happening at Protagonist Therapeutics? Insiders have sold a total of 88,457 Protagonist Therapeutics shares in the last 24 months for a total of $2,678,327.76 sold. More Insider Trading Tools from MarketBeat Related Companies: Dynavax Technologies Insider Trades Edgewise Therapeutics Insider Trades Ardelyx Insider Trades Arcus Biosciences Insider Trades Supernus Pharmaceuticals Insider Trades Zai Lab Insider Trades Agios Pharmaceuticals Insider Trades Kura Oncology Insider Trades Ligand Pharmaceuticals Insider Trades Avadel Pharmaceuticals Insider Trades Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: Pagaya Technologies: An AI Fintech That Insiders Are BuyingThe 5 Stocks Most Sold By Insiders This Year3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1The 5 Hottest CEO Stock Purchases So Far This Year3 Cheap Stocks that Insiders Bought in Q1 This page (NASDAQ:PTGX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.